


Your Ref.: 2016/12117
Our Ref.: SHU/PD20-9007CO
OA RESPONSE 15104
December 28, 2017

Amended Claims


[Claim 1]

An antibody-drug conjugate wherein an antitumor compound represented by the following formula:

[Formula 1]



is conjugated to an anti-TROP2 antibody as in the form of drug-linker structure selected from the following group:



wherein

Your Ref.: 2016/12117
Our Ref.: SHU/PD20-9007CO
OA RESPONSE 15104
December 28, 2017

said drug-linker structure is connected to anti-TROP2 antibody via a thioether bond which is formed at a disulfide bond moiety present in a hinge part of the anti-TROP2 antibody,

-GGFG- represents a peptide residue of -Gly-Gly-Phe-Gly-, and

wherein the anti-TROP2 antibody comprises CDR1 consisting of the amino acid sequence of SEQ ID NO: 23, CDR2 consisting of the amino acid sequence of SEQ ID NO: 24 and CDR3 consisting of the amino acid sequence of SEQ ID NO: 25 in its heavy chain variable region and CDR1 consisting of the amino acid sequence of SEQ ID NO: 26, CDR2 consisting of the amino acid sequence of SEQ ID NO: 27 and CDR3 consisting of the amino acid sequence of SEQ ID NO: 28 in its light chain variable region.

[Claim 2]

The antibody-drug conjugate according to claim 1, wherein the anti-TROP2 antibody comprises a heavy chain and a light chain selected from the group;
a heavy chain variable region comprising the amino acid sequence of positions 20 to 140 of SEQ ID NO: 12 and a light chain variable region comprising the amino acid sequence of positions 21 to 129 of SEQ ID NO: 18,
a heavy chain variable region comprising the amino acid sequence of positions 20 to 140 of SEQ ID NO: 14 and a light chain variable region comprising the amino acid sequence of positions 21 to 129 SEQ ID NO: 18,
a heavy chain variable region comprising the amino acid sequence of positions of 20 to 140 of SEQ ID NO: 14 and a light chain variable region comprising the amino acid sequence of positions 21 to 129 of SEQ ID NO: 20, and

a heavy chain variable region comprising the amino acid sequence of positions 20 to 140 of SEQ ID NO: 16 and a light chain variable region comprising the amino acid sequence of positions 21 to 129 of SEQ ID NO: 22.

[Claim 3]

The antibody-drug conjugate according to claim 1, wherein the anti-TROP2 antibody comprises a heavy chain and a light chain selected from the group;

a heavy chain consisting of the amino acid sequence of positions 20 to 470 of SEQ ID NO: 12 and a light chain consisting of the amino acid sequence of positions 21 to 234 of SEQ ID NO: 18,

a heavy chain consisting of the amino acid sequence of positions 20 to 470 of SEQ ID NO: 14 and a light chain consisting of the amino acid sequence of positions 21 to 234 of SEQ ID NO: 18,

a heavy chain consisting of the amino acid sequence of positions 20 to 470 of SEQ ID NO: 14 and a light chain consisting of the amino acid sequence of positions 21 to 234 of SEQ ID NO: 20, and

a heavy chain consisting of the amino acid sequence of positions 20 to 470 of SEQ ID NO: 16 and a light chain consisting of the amino acid sequence of positions 21 to 234 of SEQ ID NO: 22.

[Claim 4]

The antibody-drug conjugate according to claim 1, wherein the anti-TROP2 antibody comprises a heavy chain variable region comprising the amino acid sequence of positions 20 to 140 of SEQ ID NO: 12 and a light chain variable

Your Ref.: 2016/12117
Our Ref.: SHU/PD20-9007CO
OA RESPONSE 15104
December 28, 2017

region comprising the amino acid sequence of positions 21 to 129 of SEQ ID NO: 18.

[Claim 5]

The antibody-drug conjugate according to claim 1, wherein the anti-TROP2 antibody comprises a heavy chain consisting of the amino acid sequence of positions 20 to 470 of SEQ ID NO: 12 and a light chain consisting of the amino acid sequence of positions 21 to 234 of SEQ ID NO: 18.

[Claim 6]


The antibody-drug conjugate according to claim 3, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.

[Claim 7]

The antibody-drug conjugate according to claim 5, wherein the anti-TROP2 antibody lacks a lysine residue at the carboxyl terminus of the heavy chain.

[Claim 8]


The antibody-drug conjugate according to claim 1, wherein the drug-linker structure is:



[Claim 9]


The antibody-drug conjugate according to claim 1, wherein the drug-linker structure is:

Your Ref.: 2016/12117
Our Ref.: SHU/PD20-9007CO
OA RESPONSE 15104
December 28, 2017



[Claim 10]

The antibody-drug conjugate according to claim 1, wherein the drug-linker structure is:



[Claim 11]

The antibody-drug conjugate according to claim 1, wherein an average number of units of the selected one drug-linker structure conjugated per antibody is in a range of from 2 to 8.

[Claim 12]

The antibody-drug conjugate according to claim 1, wherein an average number of units of the selected one drug-linker structure conjugated per antibody is in a range of from 3 to 8.

[Claim 13]

A pharmaceutical composition containing the antibody-drug conjugate according to claim 1 as an active component, and a pharmaceutically acceptable formulation component.

Your Ref.: 2016/12117

Our Ref.: SHU/PD20-9007CO

OA RESPONSE 15104

December 28, 2017